Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Numinus (OTC:NUMIF) concluded its acquisition of Novamind (OTC:NVMDF) in one of the most significant cases of consolidation for the psychedelics industry this year. The takeover gives Numinus a strong entry into the U.S., with 13 operating wellness clinics across North America, four clinical research sites and a dedicated psychedelics research laboratory.
Elon Musk, Tesla (NASDAQ:TSLA) CEO and one of the most influential thought leaders of the day, shared more proof of his support for psychedelic medicine, tweeting that “psychedelics and MDMA can make a real difference to mental health, especially for extreme depression and PTSD. We should take this seriously.”
In Colorado, Governor Jared Polis signed a bill that allows for the legal possession and use of MDMA with a medical prescription, provided the drug becomes FDA-approved. This decision could put the state ahead of its peers to launch the delivery of MDMA-assisted psychotherapy after its expected approval next year.
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
Elon Musk, the Tesla multi-billionaire investor and owner of the largest portion of Twitter (NYSE:TWTR) shares, has been discussing psychedelics on the social platform. The most recent message Musk posted was a reply to a statement by Doug Drysdale, CEO of ...Read More...
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Cybin Inc. (NEO:CYBN) (NYSE:CYBN) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE:ENBI) (OTCQB:ENTBF) to accelerate...Read More…
MDMA Therapeutic Prescriptions Legalized In Colorado, Once Approved On Federal Level
Psychedelics’ struggle for acquiring legal status is ongoing, but there is promising news. While the whole list of substances is still federally illegal, the discussion has done nothing but expand in a number of states in recent years, greatly supported by clinical studies outlining...Read More...
Cannabis & Psychedelics Conferences: A List Of Events For This Second Half Of The Year
On a national scale, the current cannabis legal map includes more than two-thirds of the total number of states. That is to say, well over half the country has some form of legal cannabis, whether for medical or recreational purposes. The psychedelics map presents a different panorama...Read More...
Mindset Approved For Patent Application Involving Psilocin Derivatives For Central Nervous System Disorders
Mindset Pharma Inc. (OTCQB:MSSTF), a drug discovery & development company creating psychedelic medicines to treat neurological and psychiatric disorders, is currently working on four novel families of next-generation psychedelic compounds, as well as an innovative process to chemically...Read More...
Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder
Cybin Inc. (NEO: CYBN), the biopharma company ‘focused on progressing Psychedelics to Therapeutics’ by creating safe and effective therapeutics for patients to address various mental health disorders, has received Institutional Review Board approval to launch the first-in-human Phase 1/...Read More…
Joe Rogan Says U.S. Customs Should Take Seized Cannabis & Psychedelics And 'Rethink Their Life'
Joe Rogan, a cannabis and psychedelics advocate was not pleased about the U.S. Customs and Border Protection's (CPB) recent seizure of a shipment containing marijuana, psilocybin and MDMA from a private vehicle. Popular for his often controversial views on the Joe...Read More...
Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far
Tryp Therapeutics Inc. (OTCQB:TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases. Together with the University of Florida, the company is currently studying the effects of psilocybin administration on people who suffer from Binge...Read More...
Two Psychedelics Drug Development Companies Work To Produce Novel Plant-Based Compounds For Mental Health Disorders
Filament Health Corp. (OTCQB:FLHLF) and Jaguar Health, Inc. (NASDAQ:JAGX) have signed a letter of intent for a collaboration agreement. The deal would allow for the extension of both companies’ skillsets towards creating pharmaceutical-grade, standardized drug candidates for diagnoses such...Read More...
New Acquisition: Novamind To Buy Common Shares Of Numinus Pending Canadian Supreme Court Approval
Numinus Wellness Inc. (OTCQX:NUMIF), a company focused on the development and delivery of innovative mental health care through evidence-based psychedelic-assisted therapies, announced that its shareholders approved the issuance of common shares in connection with the proposed acquisition of...Read More...
EXCLUSIVE: Silo Wellness Announces New CEO And Issues Shareholder Letter
Silo Wellness Inc. (CSE:SILO) (OTCQB:SILFF) (FRA: 3K70), a leading global psychedelics company, announced on Thursday that its founder and chairman of the board of directors Mike Arnold is assuming the role of interim CEO. Arnold will “continue to lead the Company through its planned...Read More...
Shrooms Move Forward For Palliative Care, Optimi To Supply High-Grade Psilocybin For Private Mental Health Practitioner In CA
Optimi Health Corp. (OTCQX:OPTHF), the Canadian company producing home-grown, scalable and accessible mushroom formulations, has recently signed another supply deal. This time, the counterpart that is to receive Optimi’s natural mushrooms is ATMA Journey Centers, a facilitator of...Read More...
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
Lobe Sciences Ltd. (OTCQB:LOBEF), the Vancouver-based life sciences company focused on developing transformational psychedelic medicines through drug R&A, recently announced the implementation of a consolidation of their common shares on the basis of one post-consolidation share for every six...Read More…
Does MDMA Reduce Fear? New Study Has Implications For PTSD Treatment
Using a measurement tool called the SCR, researchers found that combining MDMA with fear extinction learning and recall therapy significantly reduced the fear felt by study participants, as compared to...Read More...
A Deeper Look At DMT Trials & Studies
Preliminary results from Phase 1 DMT clinical trial for depression support the safety and tolerability of the compound. With a world-first Phase 2 trial getting underway, we are on the cusp...Read More...
What Is THC-O And Why Is This Psychedelic Cannabinoid Three Times Stronger Than THC?
Even for laymen with a decent working knowledge of cannabis, THC-O (otherwise known as THC acetate or THC-O acetate) is a fairly unknown, non-natural cannabinoid. Unlike the more visible CBD or even THC, you won...Read More…
